George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-McDonald's, Apple, Model N, Neurocrine, HD Supply, AMD

Tue, 10th Sep 2013 12:29

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Sept. 10 (Reuters) - Some U.S. stocks to watch on Tuesday:

FUTURES CLIMB ON ROSY CHINA DATA, EASING SYRIA FEARS

U.S. stock index futures rose, putting the S&P 500 on trackfor a sixth day of gains, following another batch of rosyeconomic data out of China and as expectations eased about aWestern military strike against Syria. S&P 500 futures were up 0.65 percent, Dow Jones industrial average futures were up 0.62 percent, and Nasdaq 100 futures wereup 0.7 percent.

** APPLE INC, Monday close $506.17, up 0.5 pctpremarket

Apple is expected to introduce a cheaper version of theiPhone on Tuesday, bringing one of the industry's costliestsmartphones within reach of the masses in poorer emergingmarkets.

** MCDONALD'S CORP, Monday close $96.45, up 1 pctpremarket

The fast food chain reported a better-than-expected 1.9percent rise in global sales at established restaurants inAugust, boosted by stronger sales in Europe.

** ADVANCED MICRO DEVICES INC, Monday close $3.69,up 2 pct premarket

The chipmaker, targeting new markets as personal computersales decline, unveiled chips designed to run slot machines,factory robots, airport signs, medical equipment and otherdevices.

** MODEL N INC, Monday close $14.73, down 38 pctpremarket

The revenue management software maker forecast revenue forthe year ending September 2014 below analysts' estimates onMonday. Raymond James, Stifel Nicolaus and JPMorgan cut their ratings on the stock on Tuesday.

Analysts at Stifel said the company did not clearlyarticulate a plan to cut expenses. Raymond James analysts said areturn to revenue growth could be delayed well into 2015 unlessthe company quickly improved sales execution.

** NEUROCRINE BIOSCIENCES INC, Monday close $16.70,down 28 pct premarket

The company said on Monday that a lower dose of itsexperimental drug to treat a rare movement disorder did not meetthe main goal of a mid-stage clinical study. Cowen and Co cut its price target on the stock to $19 from $20while MKM Partners cut its target to $13.50 from $17.00 andOppenheimer to $15 from $19.

** HD SUPPLY HOLDINGS INC, Monday close $24.74, down9.5 pct premarket

The construction products supplier reported a widerquarterly loss for the second quarter due to expenses associatedwith debt restructuring. The company also forecast fiscal 2013results below analysts' estimates.

** STARWOOD PROPERTY TRUST INC, Monday close$25.04, down 4 pct premarket

The company, which finances and manages commercial mortgageloans, said it was offering 25 million shares in an underwrittenpublic offering.

** L&L ENERGY INC, Monday close $2.89, up 15 pctafter market

The coal miner's first-quarter profit more than doubled asproduction was boosted by the acquisition of two mines in Chinain November. Production rose 54 percent to 228,000 tons in thequarter.

** FIVE BELOW INC, Monday close $41.04, up 14 pctafter market

The specialty value retailer reported better-than-expectedresults for the second quarter due to a 6.6 percent increase insame-store sales. The company also raised its full-year earningsand revenue forecast.

** PVH CORP, Monday close $132.11, down 4.4 pctafter market

The maker of Calvin Klein and Tommy Hilfiger clothes gave athird-quarter sales and profit forecast that was below analysts'estimates. The company characterized the global environment as"challenging".

** BLACKBERRY LTD, Monday close $11.53, down 4 pctpremarket

The Canadian company's biggest shareholder has approachedseveral large Canadian investment funds about forging a deal totake the smartphone maker private, but the proposal is still "anairy-fairy, 'what if' kind of thing," according to a source withdirect knowledge of the situation.

** GLAXOSMITHKLINE PLC, Monday close $50.46, down 1pct premarket

The threat of generic copies of the company's best-sellinglung drug Advair finally making it to the market in the UnitedStates hit confidence in the drugmaker.

** MICROSOFT CORP, Monday close $31.65, up 1 pctpremarket

At least three of the top 20 investors in the company want aturnaround expert to succeed Steve Ballmer as chief executive.They have urged the technology giant's board to consider FordMotor Co Chief Executive Alan Mulally and ComputerSciences Corp Chief Executive Mike Lawrie for the job,several sources familiar with the matter said. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.